Search
Search Results
-
Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial
Hippocampal hyperactivity is a novel pharmacological target in the treatment of schizophrenia. We hypothesized that levetiracetam (LEV), a drug...
-
EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy
Epilepsy is one of the most frequent neurological conditions with an estimated prevalence of more than 50 million people worldwide and an annual...
-
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
The developmental and epileptic encephalopathies encompass a group of rare syndromes characterised by severe drug-resistant epilepsy with onset in...
-
Neuroimaging in psychedelic drug development: past, present, and future
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression,...
-
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
BackgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in...
-
Antiseizure Drugs and Movement Disorders
The relationship between antiseizure drugs and movement disorders is complex and not adequately reviewed so far. Antiseizure drugs as a treatment for...
-
Identification of potential crucial genes and therapeutic targets for epilepsy
BackgroundEpilepsy, a central neurological disorder, has a complex genetic architecture. There is some evidence suggesting that genetic factors play...
-
In vivo evidence of lower synaptic vesicle density in schizophrenia
Decreased synaptic spine density has been the most consistently reported postmortem finding in schizophrenia (SCZ). A recently developed in vivo...
-
NIMH perspectives on future directions in neuroimaging for mental health
NIMH’s mission is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for...
-
-
Hippocampal circuit dysfunction in psychosis
Despite strong evidence of the neurodevelopmental origins of psychosis, current pharmacological treatment is not usually initiated until after a...
-
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Novel agents addressing non-amyloid, non-tau targets in Alzheimer’s Disease (AD) comprise 70% of the AD drug development pipeline of agents currently...
-
In vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H positron emission tomography
PurposeLoss of brain synapses is an early pathological feature of Alzheimer’s disease. The current study assessed synaptic loss in vivo with positron...
-
Positron emission tomography in multiple sclerosis — straight to the target
Following the impressive progress in the treatment of relapsing–remitting multiple sclerosis (MS), the major challenge ahead is the development of...
-
Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis
IntroductionThe aim was to evaluate the efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with severely drug-resistant focal...
-
Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development
PurposeA limit on develo** new treatments for a number of central nervous system (CNS) disorders has been the inadequate understanding of the in...
-
Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
Rationale[ 11 C]-UCB-J is an emerging tool for the noninvasive measurement of synaptic vesicle density in vivo. Here, we report human biodistribution...
